Nemes Rush Group’s Denali Therapeutics DNLI Stock Holding History

Nemes Rush Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18K	Hold	700	–	–	﹤0.01%	502
2026 Q1	$13.4K	Hold	700	–	–	﹤0.01%	512
2025 Q4	$11.6K	Hold	700	–	–	﹤0.01%	531
2025 Q3	$10.2K	Hold	700	–	–	﹤0.01%	485
2025 Q2	$9.79K	Hold	700	–	–	﹤0.01%	478
2025 Q1	$9.52K	Hold	700	–	–	﹤0.01%	469
2024 Q4	$14.3K	Hold	700	–	–	﹤0.01%	432
2024 Q3	$14.4K	Hold	700	–	–	﹤0.01%	371
2024 Q2	$16.3K	Hold	700	–	–	﹤0.01%	364
2024 Q1	$14.4K	Hold	700	–	–	﹤0.01%	408
2023 Q4	$15K	Hold	700	–	–	﹤0.01%	385
2023 Q3	$14.4K	Hold	700	–	–	﹤0.01%	367
2023 Q2	$20.7K	Buy	+700	New	+$19.7K	﹤0.01%	363

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nemes Rush Group's DNLI Position: Q2 2026 in Review

Nemes Rush Group held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 700 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #502.

Nemes Rush Group first reported a position in DNLI in Q2 2023 and has held it in 13 quarters since. The position peaked at $20.7K in Q2 2023. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Nemes Rush Group held 700 shares of Denali Therapeutics worth $18K as of Q2 2026.
Nemes Rush Group left its Denali Therapeutics share count unchanged in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #502 holding.
Nemes Rush Group first reported a position in Denali Therapeutics in Q2 2023 and has held it in 13 quarters since.
Nemes Rush Group's Denali Therapeutics position peaked at $20.7K in Q2 2023.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.